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OBJECTIVE We sought to study the effects of a single oral dose of sildenafil citrate (50 mg) on blood
pressure (BP) in men taking the nitric oxide (NO) donor drugs isosorbide mononitrate
(ISMN) or glyceryl trinitrate (GTN) for stable angina.
BACKGROUND Sildenafil, a selective phosphodiesterase type 5 inhibitor, is an orally effective treatment for
erectile dysfunction. The presence of phosphodiesterases in the vasculature suggests the
possibility of an interaction between sildenafil and NO donor drugs.
METHODS Two double-blind, placebo-controlled, randomized, two-way crossover trials were under-
taken. Sixteen male patients received oral ISMN (20 mg twice a day) for five to seven days
before their dose of sildenafil or placebo and continued receiving ISMN daily until
administration of the alternate drug seven days later. For the second study, 15 male patients
received sublingual GTN (500 mg) 1 h after sildenafil or placebo on each of two study days,
which were seven days apart. Sitting or standing BP was measured before and for 6 h after
the administration of the study drug.
RESULTS The effects of sildenafil plus ISMN on BP (standing mean maximum reductions from
baseline in systolic/diastolic BP, 252/229 mm Hg) were greater than the effects of placebo
plus ISMN on BP (225/215 mm Hg; p , 0.001). Sildenafil plus GTN also resulted in
greater sitting mean maximum reductions from baseline in systolic/diastolic BP
(236/221 mm Hg) compared with placebo plus GTN (226/212 mm Hg; p , 0.01).
CONCLUSIONS Coadministration of sildenafil with ISMN or GTN produced significantly greater reductions
in BP than ISMN or GTN alone. Based on these data, sildenafil should not be administered
to patients taking nitrates. (J Am Coll Cardiol 2000;36:25–31) © 2000 by the American
College of Cardiology
Sildenafil citrate is the first effective oral treatment for
erectile dysfunction (ED) of various etiologies (1). Under
conditions of normal sexual stimulation, the penile erectile
process is regulated by release of the neurotransmitter nitric
oxide (NO), which in turn induces the production of cyclic
guanosine monophosphate (cGMP) (2,3). Increased levels
of cGMP lead to relaxation of smooth muscle in the corpus
cavernosum and to engorgement of the penis with blood,
resulting in an erection (2,3). Sildenafil, by selectively
inhibiting phosphodiesterase type 5 (PDE5), which is found
in high concentrations in the corpus cavernosum, reduces
the metabolism of cGMP and thereby facilitates achieving
and maintaining an erection satisfactory for sexual perfor-
mance (4–7).
Nitric oxide is also an important regulator of cardiovas-
cular function because it mediates tonic relaxation of vas-
cular smooth muscle (8–11). Endothelium-bound NO syn-
thase tightly controls the formation of NO from the amino
acid L-arginine (8–10,12). Release of NO activates guany-
late cyclase and the generation of cGMP (13). Once
stimulated, the NO-cGMP pathway causes vasodilation of
arteries and veins resulting in decreased preload and after-
load. Over stimulation of the NO-cGMP pathway by
administration of exogenous NO or through other mecha-
nisms could result in significant decreases in systemic blood
pressure (BP) and symptoms of hypotension.
Patients with ED of vascular etiology often suffer from
some form of atherosclerotic cardiovascular disease such as
angina. Therefore, a sizable patient population may possess
risk factors that are shared by both ED and angina. Two
commonly used therapeutics for angina are isosorbide
mononitrate (ISMN), which functions as an NO donor and
must be metabolized to release NO, and glyceryl trinitrate
(GTN), which acts within tissues to generate the produc-
tion of NO (14,15).
Administration of sildenafil alone causes modest reduc-
tions in BP (16,17), but these are not as pronounced as the
reductions in BP observed after administration of therapeu-
tic doses of nitrates used alone for control of angina (14).
Because sildenafil and NO donors act at different points in
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the same NO-cGMP pathway and PDE5 may participate
in the termination of NO-induced actions generated in
blood vessels, there is likely to be a significant interaction
when these two types of drugs are coadministered. Indeed,
an early clinical trial in normal, healthy volunteers suggested
this (18), and, as a result, the coadministration of nitrates
(or NO donors) and sildenafil is strictly contraindicated.
The two phase II clinical studies reported here further
address the interaction of nitrates and sildenafil in patients
with stable angina using a pragmatic crossover design. In
these studies, hemodynamic responses were measured for
6 h after the administration of therapeutic doses of sildenafil
to patients already using ISMN and also for 6 h after the
administration of sublingual GTN in patients who recently
had taken sildenafil.
METHODS
Patient group. Two separate studies were performed to
evaluate the cardiovascular effects of sildenafil and NO-
donor drugs administered concomitantly. The volunteer
patients recruited for these studies had a history of stable
angina and were currently being treated with oral nitrate
drugs. Table 1 presents patient demographics and baseline
measurements of the study participants. Permissible concur-
rent medications included antihypertensive agents, calcium
channel antagonists and beta-adrenergic blocking agents for
treatment of angina. Patients were excluded from the study
if there was any evidence of clinically significant diseases
other than stable angina, including a history of recent (,6
months) myocardial infarction or unstable angina. Patients
were also excluded if they had hypertension (systolic/
diastolic BP . 170/100 mm Hg) or hypotension (systolic/
diastolic BP , 100/60 mm Hg), any evidence of drug abuse
or any condition that was likely to affect the absorption of
sildenafil. Written informed consent was obtained from
each patient before study entry. The protocols were re-
viewed and approved by the local ethics committee.
ISMN study. Sixteen male patients ages 45 to 78 years
were entered into this double-blind, placebo-controlled,
randomized, two-way crossover study. All patients had
stable angina and were being treated with ISMN. All
patients received oral ISMN tablets (20 mg twice a day after
meals) beginning five to seven days before receiving a single
50-mg dose of sildenafil or placebo. Patients received
sildenafil and ISMN simultaneously on the morning of the
first study visit. Patients continued receiving ISMN treat-
ment for a minimum of seven days after the first dose of
study drug before receiving a single dose of the alternate
study drug (sildenafil or placebo) simultaneously with
ISMN at the second study visit. Sitting and standing BP
and heart rate (HR) were measured at screening, immedi-
ately before receiving sildenafil or placebo (baseline) and at
fixed intervals up to 6 h after receiving the study drug during
each study visit. The maximum change in BP and HR from
baseline was recorded. The systemic effects of the study drug
plus ISMN on BP and HR were assessed by determining
the area under the effect curve (AUEC) for BP and HR
using the trapezoidal rule. Adverse events were recorded at
each study visit, and laboratory safety tests were performed
at screening, at the end of each treatment period and at a
follow-up visit.
Abbreviations and Acronyms
AUEC 5 area under the effect curve
BP 5 blood pressure
cGMP 5 cyclic guanosine monophosphate
ED 5 erectile dysfunction
GTN 5 glyceryl trinitrate
HR 5 heart rate
ISMN 5 isosorbide mononitrate
NO 5 nitric oxide
PDE5 5 phosphodiesterase type 5
Table 1. Patient Demographics and Baseline Measurements
ISMN Study Mean (Range) GTN Study Mean (Range)
Sildenafil3Placebo
(n 5 9)
Placebo3Sildenafil
(n 5 9)
GTN3Placebo
(n 5 8)
Placebo3GTN
(n 5 8)
Age (yr) 65 (45–77) 68 (60–78) 62 (47–77) 65 (46–74)
Weight (kg) 86 (65–100) 84 (65–98) 79 (74–93) 78 (69–92)
Time since first diagnosis (yr) 7.1 (0.8–17) 9.6 (0.1–22) 7.6 (0.4–18) 4.3 (1–12.5)
Sildenafil 1 ISMN
(n 5 16)
Placebo 1 ISMN
(n 5 16)
Sildenafil 1 GTN
(n 5 15)
Placebo 1 GTN
(n 5 15)
Sitting systolic pressure (mm Hg) 137 (100–168) 142 (99–177) 129 (110–164) 130 (104–165)
Sitting diastolic pressure (mm Hg) 81 (67–96) 80 (60–94) 75 (63–93) 74 (58–92)
Heart rate (beats/min) 66 (51–90) 66 (54–92) 61 (45–74) 62 (46–75)
Concurrent medications:
ACE inhibitor or CCB 10 9 5 4
Beta-blocker 7 7 6 6
Diuretic 4 4 2 2
Vasodilator (e.g., GTN) 15 15 15 15
ACE 5 angiotensin-converting enzyme; CCB 5 calcium channel blocker; GTN 5 glyceryl trinitrate; ISMN 5 isosorbide mononitrate.
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GTN study. Fifteen male patients ages 46 to 77 years were
enrolled into this double-blind, placebo-controlled, ran-
domized, two-way crossover study. All patients had stable
angina and were receiving sublingual GTN as needed at the
time of entry into the study. During the study, patients were
permitted to take GTN as needed except on the two days
when the study drug was to be administered. On these days,
patients were instructed not to take GTN within 4 h of their
scheduled clinic visit. At the clinic visit, patients were given
a single 50-mg dose of sildenafil or placebo followed 1 h
later by a 500-mg dose of GTN administered sublingually.
The two clinic visits were separated by a minimum of seven
days; at the second visit, patients received the alternate study
drug (sildenafil or placebo) and GTN as described above.
Sitting BP and HR were measured at screening, immedi-
ately before receiving sildenafil or placebo (baseline) and at
fixed intervals up to 6 h after receiving study drug. The
maximum change in BP and HR from baseline was again
recorded. The AUECs for BP and HR were calculated for
each dosing regimen as in the first study. Adverse events
were recorded at each study visit, and laboratory safety tests
were performed at screening, at the end of each treatment
period and at a follow-up visit.
Statistics. Maximum changes from baseline in BP and HR
were determined for each individual patient. Mean maxi-
mum changes from baseline and 95% confidence intervals
were calculated for BP and HR in the sildenafil and placebo
groups. Analysis of covariance was used to determine the
significance of the differences between patients receiving
placebo or sildenafil. The between-subject and within-
subject baseline values were included in the analysis of
variance model as covariates.
RESULTS
ISMN study. All patients in this study received ISMN. In
those patients also receiving placebo, the sitting mean
maximum decrease from baseline (6SEM) in systolic/
diastolic BP was 22 6 2.5/13 6 1.9 mm Hg (Table 2). In
patients receiving ISMN plus sildenafil, the mean maximum
decrease from baseline in sitting systolic/diastolic BP was
41 6 3.8/26 6 1.9 mm Hg (p , 0.01 compared with
placebo). The BP results obtained with standing measure-
ments were even more pronounced than those obtained
while patients were sitting. In patients receiving placebo, the
standing mean maximum decrease from baseline (6SEM)
in systolic/diastolic BP was 25 6 2.8/15 6 1.3 mm Hg
(Table 3). In patients receiving sildenafil, the mean maxi-
mum decrease from baseline in standing systolic/diastolic
BP was 52 6 6.2/29 6 3.0 mm Hg (p , 0.001 compared
with placebo). When viewed over time, it is clear that
administration of ISMN plus sildenafil resulted in substan-
tially greater decreases in BP from baseline over the 6-h
recording period compared with the decreases in BP from
baseline in patients receiving ISMN plus placebo (Fig. 1 and
2). The decreases in BP were greatest from approximately 1
to 3 h after dosing and were still apparent at the 6-h time
point. The cumulative systemic effect of these changes over
time are reflected in the AUEC values for both treatment
groups (Tables 2 and 3). The decreases in the AUECs for
systolic and diastolic BP were significantly greater (p ,
0.001) for the sildenafil-treated patients compared with the
AUECs for placebo-treated patients.
The mean maximum increases from baseline in HR were
not significantly different between treatment groups (Tables
2 and 3). However, the increase in the AUEC for standing
HR was significantly greater in patients receiving sildenafil
compared with those receiving placebo (p , 0.01, Table 3).
These differences are reflected in the mean sitting and
standing changes in HR over the 6-h period (Fig. 3).
The most common adverse events associated with the
administration of ISMN were dizziness (five patients—
sildenafil, two patients—placebo), sweating (three pa-
tients—sildenafil, zero patients—placebo), postural hypo-
tension (two patients—sildenafil, one patient—placebo) and
headache (two patients—sildenafil, one patient—placebo).
All treatment-emergent adverse events during the sildenafil
and placebo study periods were mild to moderate in severity
and were considered treatment-related. No serious adverse
Table 2. Sitting Mean Maximum Changes From Baseline and AUEC After Receiving Sildenafil or Placebo in Patients
Concomitantly Receiving Oral ISMN (20 mg) Treatment*
Sildenafil, 50 mg Mean
(Range)
Placebo Mean
(Range) p Value
Systolic Blood Pressure
Maximum decrease (mm Hg) 241.0 (26 to 270) 222.1 (22 to 234) ,0.01
AUEC (mm Hgzh) 2127.6 (27 to 2235) 245.9 (56 to 2158) ,0.001
Diastolic Blood Pressure
Maximum decrease (mm Hg) 225.8 (215 to 242) 212.7 (21 to 225) ,0.0001
AUEC (mm Hgzh) 298.2 (240 to 2188) 225.2 (76 to 2123) ,0.0001
Heart Rate
Maximum increase (beats/min) 15.8 (21 to 36) 14.0 (1 to 39) 0.35
AUEC (beats/minzh) 33.0 (240 to 181) 23.3 (236 to 165) 0.12
*n 5 16 (adjusted arithmetic means).
AUEC 5 area under effect curve.
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events were reported, and there were no reports of clinically
significant tachycardia in either treatment group. There
were no treatment-related abnormalities in laboratory test
results.
GTN study. All patients in this study received GTN 1 h
after receiving placebo or sildenafil (arrow, Fig. 4). In
patients who also received placebo, the mean maximum
Figure 1. Mean changes from baseline in sitting systolic (A) and diastolic
(B) BP after ISMN administration. Sildenafil plus ISMN caused signifi-
cant decreases in systolic and diastolic BP compared with placebo plus
ISMN. Oral ISMN (20 mg) and oral sildenafil (50 mg) or placebo were
administered at time 0, as indicated by the arrows. Baseline (time 0) is the
average of the measurements taken immediately before sildenafil or placebo
administration. Values represent mean 6 SEM; n 5 16; BP 5 blood
pressure; ISMN 5 isosorbide mononitrate.
Figure 2. Mean changes from baseline in standing systolic (A) and
diastolic (B) BP after ISMN administration. Sildenafil plus ISMN caused
significant decreases in systolic and diastolic BP compared with placebo
plus ISMN. Oral ISMN (20 mg) and oral sildenafil (50 mg) or placebo
were administered at time 0, as indicated by the arrows. Baseline (time 0)
is the average of the measurements taken immediately before sildenafil or
placebo administration. Values represent mean 6 SEM; n 5 16; BP 5
blood pressure; ISMN 5 isosorbide mononitrate.
Table 3. Standing Mean Maximum Changes From Baseline and AUEC After Receiving Sildenafil or Placebo in Patients
Concomitantly Receiving Oral ISMN (20 mg) Treatment*
Sildenafil, 50 mg Mean
(Range)
Placebo Mean
(Range) p Value
Systolic Blood Pressure
Maximum decrease (mm Hg) 251.6 (217 to 290) 224.5 (21 to 249) ,0.001
AUEC (mm Hgzh) 2166.2 (25 to 2363) 257.9 (70 to 2150) ,0.001
Diastolic Blood Pressure
Maximum decrease (mm Hg) 229.3 (211 to 2 49) 214.8 (25 to 222) ,0.001
AUEC (mm Hgzh) 2109.9 (240 to 2215) 239.4 (46 to 291) ,0.0001
Heart Rate
Maximum increase (beats/min) 18.5 (25 to 41) 17.1 (4 to 40) 0.38
AUEC (beats/minzh) 57.1 (253 to 168) 35.8 (252 to 151) ,0.01
*n 5 16 (adjusted arithmetic means).
AUEC 5 area under effect curve.
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decrease from baseline (6SEM) in sitting systolic/diastolic
BP was 26 6 3.6/11 6 1.9 mm Hg (Table 4). In patients
receiving sildenafil, the mean maximum decrease from
baseline in systolic/diastolic BP was 36 6 4.8/21 6
2.1 mm Hg (p , 0.01 compared with placebo). These
decreases are apparent when viewed over the 6-h recording
period (Fig. 4), during which it can be seen that the greatest
differences in BP measurements between the sildenafil and
placebo treatment groups occurred within 1 h after GTN
administration. The differences between the two groups
were still apparent at the 6-h time point. As with the ISMN
study, the cumulative systemic effects of these changes are
reflected in the AUEC values (Table 4). The decreases in
the AUECs were significantly greater for systolic BP (p ,
0.01) and diastolic BP (p , 0.001) in the sildenafil-treated
patients compared with the AUECs in the placebo-treated
patients.
Minimal mean changes in HR occurred until the admin-
istration of GTN at 1 h (arrow, Fig. 5). From that point,
there were significantly greater (p , 0.01) mean maximum
increases from baseline in sitting HR in patients receiving
sildenafil compared with the HR in patients receiving
placebo (Table 4). The increases in the AUECs for HR
were not significantly different between patients receiving
sildenafil and GTN and those receiving placebo and GTN
(Table 4), suggesting that the effects on HR were transient
in nature.
Eight patients reported an adverse event after sildenafil
treatment compared with four patients reporting an adverse
event after placebo treatment. The most common adverse
events associated with the administration of sildenafil were
headache (five patients) and dizziness (three patients). Of
these, headache in one patient and dizziness in two patients
were considered treatment-related. No treatment-related
adverse events occurred after administration of placebo. No
serious adverse events or laboratory test abnormalities re-
lated to treatment were reported.
One patient was withdrawn from the sildenafil/GTN
group with lowered BP. Six minutes after GTN adminis-
tration (1 h, 6 min after sildenafil) he reported feeling
unwell and had a mild headache. At baseline his BP reading
was 167/88, and 56 min after taking sildenafil, his reading
was 155/80. Ten minutes later (6 min after taking GTN),
his BP reading was 86/47 and dropped further to 70/39
during the next 6 min. His systolic pressure remained below
Figure 3. Mean changes from baseline in sitting (A) or standing (B) heart
rate after ISMN administration. Oral ISMN (20 mg) and oral sildenafil
(50 mg) or placebo were administered at time 0, as indicated by the arrow.
Baseline (time 0) is the average of the measurements taken immediately
before sildenafil or placebo administration. Values represent mean 6 SEM;
n 5 16; bpm 5 beats per minute; HR 5 heart rate; ISMN 5 isosorbide
mononitrate.
Figure 4. Mean changes from baseline in sitting systolic (A) and diastolic
(B) BP after GTN administration. Sildenafil plus GTN caused significant
decreases in systolic and diastolic BP compared with placebo plus sildenafil.
Sublingual GTN (500 mg) was administered 1 h after oral sildenafil
(50 mg), as indicated by the arrow. Baseline (time 0) is the average of the
measurements taken immediately before sildenafil or placebo administra-
tion. Values represent mean 6 SEM; n 5 15; BP 5 blood pressure;
GTN 5 glyceryl trinitrate.
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100 mm Hg for an additional 9 min and did not rise above
130 mm Hg until 43 min after receiving GTN.
DISCUSSION
Treatment of stable angina with nitrates or NO donors is
based on their rapid onset of action and vasodilator capacity
(14). Evidence from other clinical trials suggested that
sildenafil in combination with acute doses of GTN could
result in synergistic decreases of BP (18). This study has
expanded on these findings, demonstrating that nitrate-
sildenafil hemodynamic interactions affecting BP persisted
during the entire 6-h observation period. Furthermore, the
present studies were conducted in patients using a trial
design that more closely reflects the interactions likely to be
observed with an unintentional coadministration of these
two classes of drugs.
Study drugs alone. The magnitude of the BP-lowering
effects observed after administration of ISMN alone (sitting
and standing mean maximum decreases of 22/13 and
25/15 mm Hg) and of GTN alone (sitting mean maximum
decrease of 26/11 mm Hg) were substantially greater than
the BP-lowering effect previously observed after adminis-
tration of sildenafil alone. In early clinical trials, the effect of
high doses of sildenafil on BP in healthy men was modest,
producing mean maximum decreases of systolic/diastolic BP
of 10/7 mm Hg that were not dose-related (16,17).
Sildenafil-nitrate interaction. Because vasodilation is
known to be mediated by changes in cGMP levels, and
treatment with nitrates and sildenafil both result in increas-
ing intracellular levels of cGMP, an interaction during
concomitant administration was anticipated (6,13,19). In
the studies reported here, sitting mean maximum decreases
of 41/26 mm Hg were observed in patients receiving ISMN
and sildenafil, and sitting mean maximum decreases of
36/21 mm Hg were observed in patients receiving GTN and
sildenafil. However, the combination of ISMN and silde-
nafil produced an even larger interaction when BP was
measured standing, with mean maximum decreases of
52/29 mm Hg observed. At a minimum, the effects on BP
after coadministration of either ISMN or GTN with
sildenafil appeared to be additive, with the possibility that a
synergistic interaction was occurring, as reflected in the
standing ISMN plus sildenafil BP recordings. By inhibiting
the breakdown of cGMP, sildenafil was able to amplify the
NO-related activity of exogenously administered ISMN and
GTN on the vascular system, resulting in clinically signifi-
cant reductions in BP.
The biochemical mechanism whereby sildenafil exerts an
effect on BP is probably a result of the presence of PDE5 in
the vasculature (20). Sildenafil has considerably lower affin-
ity for other PDE isoforms involved in cardiovascular
regulation. Phosphodiesterase type 1, PDE2 and PDE3 are
located in myocardium, and PDE1 and PDE3 are located in
vascular smooth muscle; but their IC50 values for sildenafil
range from 20- to 8,000-fold higher compared with the
IC50 value of sildenafil for PDE5 (6,7,20). The low level of
vascular side effects after sildenafil treatment in placebo-
controlled and open-label clinical trials is, therefore, not
surprising (21). There are no known effects of sildenafil on
myocardial tissue or the functioning of the heart, consistent
Figure 5. Mean changes from baseline in sitting heart rate after GTN
administration. Sublingual GTN (500 mg) was administered 1 h after oral
sildenafil (50 mg), as indicated by the arrow. Baseline (time 0) is the
average of the measurements taken immediately before sildenafil or placebo
administration. Values represent mean 6 SEM; n 5 15; bpm 5 beats per
minute; HR 5 heart rate; GTN 5 glyceryl trinitrate.
Table 4. Mean Maximum Changes From Baseline and AUEC After Receiving Sildenafil or Placebo in Patients Concomitantly
Receiving Sublingual GTN (500 mg) Treatment*
Sildenafil, 50 mg
Mean (Range)
Placebo Mean
(Range) p Value
Systolic Blood Pressure
Maximum decrease (mm Hg) 235.9 (215 to 284) 226.0 (23 to 252) ,0.01
AUEC (mm Hgzh) 265.6 (6 to 2252) 228.8 (57 to 2119) ,0.01
Diastolic Blood Pressure
Maximum decrease (mm Hg) 221.1 (211 to 234) 211.4 (4 to 225) ,0.01
AUEC (mm Hgzh) 246.6 (22 to 2121) 215.1 (44 to 254) ,0.001
Heart Rate
Maximum increase (beats/min) 15.8 (3 to 31) 10.2 (1 to 15) ,0.01
AUEC (beats/minzh) 27.2 (218 to 87) 15.0 (213 to 46) 0.15
*n 5 15 (adjusted arithmetic means).
AUEC 5 area under effect curve.
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with the fact that there is no measurable level of PDE5 in
the myocardium (22).
Toleration. Mild-to-moderate adverse events were re-
ported in each study, including those related to vasodilation,
such as headache and dizziness. Treatment-related adverse
events were reported by 8 of 16 patients after ISMN and
sildenafil coadministration, and 3 of 15 patients after GTN
and sildenafil coadministration. In large-scale, double-
blind, placebo-controlled clinical trials and in open-label
extension studies, sildenafil was shown to be well-tolerated,
with a low incidence of cardiovascular-related adverse events
reported (21). These patients were not permitted to take
nitrates or NO-donor drugs, because of the potential
interaction with sildenafil. In these same trials, patients
receiving concomitant treatment with antihypertensive
medications, including vasodilators, reported no increase in
adverse events or cardiovascular-related adverse events (20).
As the antihypertensive medications were not NO donors,
they were not expected to produce a similar interaction with
sildenafil to that observed with nitrates.
Conclusions. The studies reported here have demonstrated
that marked and clinically significant reductions in BP occur
when sildenafil is administered concurrently with NO do-
nors that are commonly used to treat angina. Based on these
data, sildenafil should not be coadministered to patients
taking nitrates.
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